Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Tg Therapeutics has reported Shares Outstanding (Weighted Average) over the past 10 years, most recently at $144.3 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $144.3 million for Q4 2025, down 0.69% from a year ago — trailing twelve months through Dec 2025 was $144.3 million (down 0.69% YoY), and the annual figure for FY2025 was $144.3 million, down 0.69%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $144.3 million at Tg Therapeutics, down from $145.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for TGTX hit a ceiling of $146.7 million in Q2 2025 and a floor of $131.9 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $141.5 million (2023), compared with a mean of $139.9 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 25.07% in 2021 and later decreased 0.69% in 2025.
  • Tg Therapeutics' Shares Outstanding (Weighted Average) stood at $132.2 million in 2021, then increased by 2.41% to $135.4 million in 2022, then increased by 4.83% to $142.0 million in 2023, then rose by 2.37% to $145.3 million in 2024, then fell by 0.69% to $144.3 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $144.3 million (Q4 2025), $145.4 million (Q3 2025), and $146.7 million (Q2 2025) per Business Quant data.